Medicare Enrolled

Dr. Sreedhar Mandayam, M.D.

Nephrology · Houston, TX
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Speaking/Promotional
1515 HOLCOMBE BLVD, Houston, TX 77030
7137926161
In practice since 2006 (19 years)
NPI: 1225051048 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Mandayam from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Mandayam? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Mandayam

Dr. Sreedhar Mandayam is a nephrology in Houston, TX, with 19 years in practice. Based on federal Medicare data, Dr. Mandayam performed 788 Medicare services across 445 unique beneficiaries.

Between the years covered by Open Payments, Dr. Mandayam received a total of $662,548 from 51 pharmaceutical and/or device companies across 975 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in nephrology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Mandayam is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ 788 Medicare services$ $662,548 industry payments

Medicare Practice Summary

Medicare Utilization ↗
788
Medicare services
Bottom 33% in TX for nephrology
Lower Medicare volume may reflect subspecialty focus, hospital-based work, or a higher share of non-Medicare patients.
445
Unique beneficiaries
$108
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~41 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Hospital follow-up visit, high complexity331$95$286
Initial hospital admission, high complexity117$140$674
Critical care, first 30-74 min117$173$992
Hemodialysis, single evaluation73$58$644
Office visit, established patient (30-39 min)53$71$266
Hospital follow-up visit, moderate complexity37$64$225
New patient office visit, complex (60-74 min)28$143$571
New patient office visit (45-59 min)19$99$458
Office visit, established patient (20-29 min)13$36$170
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$662,548
Total received (2018-2024)
Avg $94,650/year across 7 years
Top 0% in TX for nephrology
51
Companies
975
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$580,948 (87.7%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$66,714 (10.1%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$14,886 (2.2%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$117,907
2023
$147,235
2022
$123,719
2021
$59,488
2020
$56,925
2019
$146,327
2018
$10,947

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
CALLIDITAS THERAPEUTICS US INC.
$101,791
Otsuka America Pharmaceutical, Inc.
$91,970
Mallinckrodt Enterprises LLC
$84,928
Bayer HealthCare Pharmaceuticals Inc.
$63,086
Calliditas Therapeutics US Inc.
$61,817
Horizon Therapeutics plc
$44,024
Alexion Pharmaceuticals, Inc.
$35,811
GENZYME CORPORATION
$26,652
Travere Therapeutics, Inc.
$25,120
Janssen Pharmaceuticals, Inc
$23,214
Mallinckrodt Hospital Products Inc.
$20,417
Bayer Healthcare Pharmaceuticals Inc.
$18,984
AMAG Pharmaceuticals, Inc.
$13,470
Novartis Pharmaceuticals Corporation
$12,571
Amgen Inc.
$9,616
Kyowa Kirin, Inc.
$8,629
Otsuka Pharmaceutical Development & Commercialization, Inc.
$8,054
AstraZeneca Pharmaceuticals LP
$1,720
Relypsa, Inc.
$1,719
Merck Sharp & Dohme LLC
$1,395
Roche Products Limited
$1,308
NxStage Medical, Inc.
$904
GlaxoSmithKline, LLC.
$638
Aurinia Pharma U.S., Inc.
$638
BAXTER HEALTHCARE
$495
Vifor Pharma, Inc.
$399
Fresenius USA Marketing, Inc.
$384
Novo Nordisk Inc
$296
OPKO Pharmaceuticals, LLC
$254
AKEBIA THERAPEUTICS INC
$253
Horizon Pharma plc
$231
Baxter Healthcare
$219
Keryx Biopharmaceuticals, Inc.
$200
Ardelyx, Inc.
$149
Bard Peripheral Vascular, Inc.
$143
Vertex Pharmaceuticals Incorporated
$129
Pharming Healthcare, Inc.
$127
Rhythm Pharmaceuticals, Inc.
$112
Mallinckrodt LLC
$104
VERTEX PHARMACEUTICALS INCORPORATED
$90
Retrophin, Inc.
$81
Apellis Pharmaceuticals, Inc.
$66
ACACIA PHARMA INC
$63
Kaneka Pharma America LLC
$57
AngioDynamics, Inc.
$49
Outset Medical Inc
$46
BTG International, Inc.
$39
Allergan Inc.
$27
B. Braun Medical Inc.
$23
SANOFI-AVENTIS U.S. LLC
$18
Daiichi Sankyo Inc.
$17
Top 3 companies account for 42.1% of total payments
Associated products mentioned in payments ›
2008T BLUESTAR HEMODIALYSIS MACHINE · ACTHAR · ANDEXXA · AURYXIA · Aranesp · Auryxia · BENLYSTA · BYFAVO · CABLIVI · CRIT-LINE · Critline - Monitors · Crysvita · DALVANCE · DIALOG+ · ENJAYMO · FABRAZYME · FARXIGA · FERAHEME · Fabhalta · Gazyva · IBSRELA · INJECTAFER · INVOKANA · Imcivree · JESDUVROQ · JYNARQUE · KRYSTEXXA · Kerendia · LIBERTY SELECT CYCLER · LOKELMA · LUPKYNIS · NXSTAGE CARTRIDGE EXPRESS · NXSTAGE SYSTEM ONE · Ozempic · Parsabiv · RAYALDEE · RUCONEST · Rayaldee · Renal - Acute · Renal - CRRT · Renal - Dianeal Solution · Renal - Non Product Related · Renal - PrisMax System · Renal - Prismaflex System · Repatha · SAMSCA · SOLIRIS · SYSTEM ONE · System One · TARPEYO · TAVNEOS · TERLIVAZ · Thiola · ULTOMIRIS · Ultomiris · VORAXAZE · Velphoro · Veltassa · Voraxaze · XPHOZAH 30 MG
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (88%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in nephrology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 0% for nephrology in TX.

Equivalent to $84,080 per 100 Medicare services performed
Looking for a nephrology in Houston?
Compare nephrologys in the Houston area by procedure volume, costs, and industry payment transparency.
Browse nephrologys nearby

Geographic Context

Nephrologys within 10 mi
185
Per 100K population
3.9
County median income
$73,104
Nearest hospital
MEMORIAL HERMANN - TEXAS MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Mandayam is a clinical cardiology specialist, with moderate Medicare volume, and high industry engagement (speaking/promotional, top 0%), with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Mandayam experienced with hospital follow-up visit, high complexity?
Based on Medicare claims data, Dr. Mandayam performed 331 hospital follow-up visit, high complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Mandayam receive payments from pharmaceutical companies?
Yes. Dr. Mandayam received a total of $662,548 from 51 companies across 975 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Mandayam's costs compare to other nephrologys in Houston?
Dr. Mandayam's average Medicare payment per service is $108. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Mandayam) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →